Pablo G. Legorreta is CEO & Chairman at Royalty Pharma plc (RPRX). They have made 6 open-market trades across 2 companies since 2020, most recently 2026-08-05.
CIK 0001507678
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $136.7M since 2020, never a sale. Across 6 scored buys the stock is down 14.1% at ninety days, and 17.4 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 17% | 0% |
| Avg Move | -6.0% | -8.1% | -14.1% |
| Alpha | -6.8% | -12.4% | -17.4% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PROK | BUY | 2024-06-13 | 2024-06-14 | $2.42 | $109.5M | -17.7% | -18.7% | -19.0% |
| RPRX | BUY | 2023-06-28 | 2023-06-28 | $29.51 | $3.8M | +3.0% | +4.7% | -10.4% |
| RPRX | BUY | 2023-06-12 | 2023-06-13 | $32.89 | $3.0M | -9.3% | -7.2% | -12.4% |
| RPRX | BUY | 2023-05-24 | 2023-05-24 | $32.25 | $4.8M | +5.0% | -3.9% | -8.1% |
| RPRX | BUY | 2023-05-16 | 2023-05-17 | $33.38 | $15.4M | -3.0% | -4.9% | -11.1% |
| RPRX | BUY | 2020-06-18 | 2020-06-22 | $28.00 | $280K | -13.7% | -18.7% | -23.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.